Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media.
Agfa HealthCare has signed an agreement with Curagita Holding AG to acquire all the shares of its subsidiary Insight Agents GmbH, a German-based developer and producer of generic contrast media. Agfa expects to pay about 10 million Euros for the contrast media firm in a deal that the Belgian company is framing as an important strategic step towards future growth opportunities. Insight Agents makes generic contrast media, including the MR contrast agent Magnegita (gadopentetate dimeglumine), a generic form of Magnevist, and Iopamigita (Iopamidol), a generic form of Isovue. Insight’s contrast media are logical additions to Agfa’s portfolio of film, chemicals, and printers, according to Christian Reinaudo, president of Agfa HealthCare. They will be distributed through the company’s extensive logistics and distribution network, he said.
Can Innovations with AI Help Address the Impact of Staffing Shortages on Radiology Workflow?
October 7th 2024While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.
CT Study Links Pleural Effusion and Higher 30-Day Mortality Rates in Patients with COVID-19
October 1st 2024In a multicenter study of over 1,100 patients with COVID-19, pleural effusion was detected on CT scans in nearly a third of patients, who also had significantly higher ICU admission and 30-day mortality rates.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.